纤维蛋白原缺乏减少载脂蛋白(a)转基因小鼠中载脂蛋白(a)的血管蓄积及动脉粥样硬化的发展。
Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.
作者信息
Lou X J, Boonmark N W, Horrigan F T, Degen J L, Lawn R M
机构信息
Falk Cardiovascular Research Center, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
出版信息
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12591-5. doi: 10.1073/pnas.95.21.12591.
Abstract
To test directly whether fibrin(ogen) is a key binding site for apolipoprotein(a) [apo(a)] in vessel walls, apo(a) transgenic mice and fibrinogen knockout mice were crossed to generate fibrin(ogen)-deficient apo(a) transgenic mice and control mice. In the vessel wall of apo(a) transgenic mice, fibrin(ogen) deposition was found to be essentially colocalized with focal apo(a) deposition and fatty-streak type atherosclerotic lesions. Fibrinogen deficiency in apo(a) transgenic mice decreased the average accumulation of apo(a) in vessel walls by 78% and the average lesion (fatty streak type) development by 81%. Fibrinogen deficiency in wild-type mice did not significantly reduce lesion development. Our results suggest that fibrin(ogen) provides one of the major sites to which apo(a) binds to the vessel wall and participates in the generation of atherosclerosis.
摘要
为了直接测试纤维蛋白（原）是否是载脂蛋白(a)[apo(a)]在血管壁中的关键结合位点，将apo(a)转基因小鼠和纤维蛋白原敲除小鼠进行杂交，以产生缺乏纤维蛋白（原）的apo(a)转基因小鼠和对照小鼠。在apo(a)转基因小鼠的血管壁中，发现纤维蛋白（原）沉积与局灶性apo(a)沉积和脂肪条纹型动脉粥样硬化病变基本共定位。apo(a)转基因小鼠中纤维蛋白原缺乏使血管壁中apo(a)的平均积累减少78%，平均病变（脂肪条纹型）发展减少81%。野生型小鼠中纤维蛋白原缺乏并未显著降低病变发展。我们的结果表明，纤维蛋白（原）是apo(a)与血管壁结合的主要位点之一，并参与动脉粥样硬化的形成。
相似文献
1
Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice.纤维蛋白原缺乏减少载脂蛋白(a)转基因小鼠中载脂蛋白(a)的血管蓄积及动脉粥样硬化的发展。
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12591-5. doi: 10.1073/pnas.95.21.12591.
2
Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.纤维蛋白原缺乏与小鼠动脉粥样硬化的发展是相容的。
J Clin Invest. 1998 Mar 1;101(5):1184-94. doi: 10.1172/JCI1461.
3
Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice.载脂蛋白(a)和载脂蛋白B对小鼠主动脉近端脂肪病变发展的相对贡献。
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1911-6. doi: 10.1161/01.atv.15.11.1911.
4
The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition.组织因子和载脂蛋白(a)在人主动脉粥样硬化病变中的定位及其与纤维蛋白原-纤维蛋白转变的关系。
Pathol Res Pract. 1996 Mar;192(3):224-32. doi: 10.1016/S0344-0338(96)80225-1.
5
Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.纤维蛋白（原）αC结构域中新型赖氨酸非依赖性载脂蛋白(a)结合位点的鉴定与表征
J Biol Chem. 2003 Sep 26;278(39):37154-9. doi: 10.1074/jbc.M305154200. Epub 2003 Jul 9.
6
Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains.
J Biol Chem. 2000 Dec 8;275(49):38206-12. doi: 10.1074/jbc.M003640200.
7
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.载脂蛋白(a)赖氨酸结合位点的修饰可减轻转基因小鼠的动脉粥样硬化。
J Clin Invest. 1997 Aug 1;100(3):558-64. doi: 10.1172/JCI119565.
8
Atherogenesis in transgenic mice expressing human apolipoprotein(a).
Nature. 1992 Dec 17;360(6405):670-2. doi: 10.1038/360670a0.
9
Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).表达人载脂蛋白B-100的低密度脂蛋白受体阴性小鼠在普通饮食条件下会形成复杂的动脉粥样硬化病变：载脂蛋白(a)不会加重病变。
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4544-9. doi: 10.1073/pnas.95.8.4544.
10
Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).携带人载脂蛋白B和脂蛋白(a)的转基因小鼠的动脉粥样硬化形成
J Clin Invest. 1995 Sep;96(3):1639-46. doi: 10.1172/JCI118203.
引用本文的文献
1
Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran.凝血因子V莱顿突变而非凝血因子II 20210G>A突变是早发性冠状动脉疾病的危险因素：伊朗的一项病例对照研究。
Res Pract Thromb Haemost. 2023 Jan 11;7(1):100048. doi: 10.1016/j.rpth.2023.100048. eCollection 2023 Jan.
2
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.钙化性主动脉瓣疾病：从分子和细胞机制到医学治疗。
Eur Heart J. 2022 Feb 12;43(7):683-697. doi: 10.1093/eurheartj/ehab757.
3
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.Xa 因子抑制在心血管预防中的多效作用：机制见解及其对抗血栓治疗的影响。
Cardiovasc Res. 2021 Jul 27;117(9):2030-2044. doi: 10.1093/cvr/cvaa263.
4
Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.凝血蛋白酶和 PARs（蛋白酶激活受体）在炎症性疾病小鼠模型中的作用。
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24. doi: 10.1161/ATVBAHA.118.311655.
5
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.钙化性主动脉瓣狭窄中的脂蛋白(a)与氧化磷脂
Curr Opin Cardiol. 2016 Jul;31(4):440-50. doi: 10.1097/HCO.0000000000000300.
6
Lipoprotein(a) metabolism: potential sites for therapeutic targets.脂蛋白(a)代谢：潜在的治疗靶点。
Metabolism. 2013 Apr;62(4):479-91. doi: 10.1016/j.metabol.2012.07.024. Epub 2012 Oct 4.
7
Fibulin-1 and fibrinogen in human atherosclerotic lesions.纤维结合蛋白-1 和纤维蛋白原在人动脉粥样硬化病变中的作用。
Histochem Cell Biol. 2009 Nov;132(5):559-65. doi: 10.1007/s00418-009-0628-7. Epub 2009 Aug 20.
8
Blood coagulation and the risk of atherothrombosis: a complex relationship.血液凝固与动脉粥样硬化血栓形成风险：一种复杂的关系。
Thromb J. 2004 Dec 1;2(1):12. doi: 10.1186/1477-9560-2-12.
9
Fibrin-mediated protection against infection-stimulated immunopathology.纤维蛋白介导的针对感染刺激的免疫病理学的保护作用。
J Exp Med. 2003 Mar 17;197(6):801-6. doi: 10.1084/jem.20021493. Epub 2003 Mar 10.
10
Genetic modifiers of atherosclerosis in mice.小鼠动脉粥样硬化的基因修饰因子。
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2336-45. doi: 10.1161/01.atv.20.11.2336.
本文引用的文献
1
Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.纤维蛋白原缺乏与小鼠动脉粥样硬化的发展是相容的。
J Clin Invest. 1998 Mar 1;101(5):1184-94. doi: 10.1172/JCI1461.
2
Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus.脂蛋白（a）在小鼠体内的血管积聚。使用重组腺病毒对赖氨酸结合位点作用的体内分析。
J Clin Invest. 1997 Sep 15;100(6):1493-500. doi: 10.1172/JCI119671.
3
Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.载脂蛋白(a)赖氨酸结合位点的修饰可减轻转基因小鼠的动脉粥样硬化。
J Clin Invest. 1997 Aug 1;100(3):558-64. doi: 10.1172/JCI119565.
4
Cholesterol and coronary heart disease. The 21st century.胆固醇与冠心病。21世纪。
Arch Intern Med. 1997 Jun 9;157(11):1177-84.
5
Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice.转基因载脂蛋白(a)小鼠局灶性血管病变形成的反馈机制。
J Biol Chem. 1996 Dec 6;271(49):31367-71. doi: 10.1074/jbc.271.49.31367.
6
Migration of cultured vascular smooth muscle cells into non-crosslinked fibrin gels.
Thromb Res. 1996 Oct 15;84(2):129-36. doi: 10.1016/0049-3848(96)00168-5.
7
The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition.组织因子和载脂蛋白(a)在人主动脉粥样硬化病变中的定位及其与纤维蛋白原-纤维蛋白转变的关系。
Pathol Res Pract. 1996 Mar;192(3):224-32. doi: 10.1016/S0344-0338(96)80225-1.
8
Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study.55岁及以下男性血浆脂蛋白(a)升高与冠心病：一项前瞻性研究。
JAMA. 1996 Aug 21;276(7):544-8. doi: 10.1001/jama.1996.03540070040028.
9
Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men.高甘油三酯血症和脂蛋白(a)升高是中年男性发生主要冠状动脉事件的危险因素。
Am J Cardiol. 1996 Jun 1;77(14):1179-84. doi: 10.1016/s0002-9149(96)00159-2.
10
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway.纤维蛋白原通过依赖细胞间黏附分子-1（ICAM-1）的途径介导白细胞与血管内皮的黏附。
Cell. 1993 Jul 2;73(7):1423-34. doi: 10.1016/0092-8674(93)90367-y.
Zotero 插件